UroGen Pharma Ltd (NASDAQ:URGN) shares, rose in value on Friday, July 11, with the stock price down by -2.73% to the previous day’s close as strong demand from buyers drove the stock to $14.24.
Actively observing the price movement in the last trading, the stock closed the session at $14.64, falling within a range of $13.91 and $14.64. The value of beta (5-year monthly) was 0.398. Referring to stock’s 52-week performance, its high was $18.15, and the low was $3.42. On the whole, URGN has fluctuated by 101.99% over the past month.
With the market capitalization of UroGen Pharma Ltd currently standing at about $656.57 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-12.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that URGN’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the price of URGN currently trading nearly 4.79% and 42.62% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 64.26, while the 7-day volatility ratio is showing 5.61% which for the 30-day chart, stands at 11.96%. Furthermore, UroGen Pharma Ltd (URGN)’s beta value is 1.11.
A comparison of UroGen Pharma Ltd (URGN) with its peers suggests the former has fared considerably weaker in the market. URGN showed an intraday change of -2.73% in last session, and over the past year, it grew by 33.71%%.
Data on historical trading for UroGen Pharma Ltd (NASDAQ:URGN) indicates that the trading volumes over the past 10 days have averaged 1.35 and over the past 3 months, they’ve averaged 3.00 million. According to company’s latest data on outstanding shares, there are 46.10 million shares outstanding.
Nearly 14.08% of UroGen Pharma Ltd’s shares belong to company insiders and institutional investors own 96.76% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 6.13 million shares as on 2025-06-13, resulting in a short ratio of 1.11. According to the data, the short interest in UroGen Pharma Ltd (URGN) stood at 1356.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 5.59 million. The stock has fallen by -14.53% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the URGN stock heading into the next quarter.
